P1, N=42, Active, not recruiting, Broadenbio Ltd., Co. | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> May 2025

P2, N=79, Not yet recruiting, Nationwide Children's Hospital

P1/2, N=140, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting

Remarkably, pazopanib treatment reversed the bleomycin-induced elevation in transforming growth factor-beta-1 (TGF-β1) and α-smooth muscle actin (α-SMA) levels. Our research highlighted the beneficial role of pazopanib in attenuating bleomycin-elicited lung fibrosis through the suppression of MEKK2 and MEKK3 and the modulation of JNK and P38 cascades.

Jingui Shenqi pill can exert therapeutic effects on cardiorenal syndrome by inhibiting the activation of the MAPK signaling pathway and inflammatory responses.

(4) Our findings indicate that CE2 expression is upregulated in PH/DEN cells, with a notable decrease in the presence of M1 macrophages. In contrast, compared with control macrophages, M1 macrophages did not significantly affect Mapk4/7 expression.

Using freeze-drying methods, three formular nontargeted microbubbles (NMBs-1, NMBs-2, NMBs-3) were prepared, and three corresponding MBE-selectin suspensions (MBE-selectin-1, MBE-selectin-2, MBE-selectin-3) were constructed via maleimide-thiol conjugation chemistry. In conclusion, we successfully prepared a novel MBE-selectin suspension carrying an anti-E-selectin antibody that can be used for intravenous injection and can enhance ultrasound imaging of the kidney as a UCA, particularly in a cisplatin-induced AKI model. Ultrasound molecular imaging of the MBE-selectin suspension may be helpful for evaluating renal microcirculation or injury in AKI diseases.

P1, N=217, Recruiting, BeiGene | N=107 --> 217

ORPH was able to improve depression-like behaviors and that it took effects by promoting cerebral blood flow, inhibition of hypothalamic-pituitary-adrenal axis overactivation, improving the structural damage of hippocampal tissues, and inhibiting the inflammatory response. ORPH can reduced neuronal damage and inhibiting apoptosis by promoting the MAPK pathway.

Furthermore, compound 21 effectively inhibited phosphorylation of the downstream adaptor protein SLP76 and enhanced IL-2 secretion in human Jurkat T cells. Taken together, this study further validates macrocyclization as an effective strategy for designing HPK1 inhibitors with innovative scaffolds and offers compound 21 as a structurally novel lead compound for the development of HPK1 inhibitors.

P1/2, N=170, Active, not recruiting, Treadwell Therapeutics, Inc | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

In CT26 models, compound 39 synergized with anti-PD-1 (60% tumor growth inhibition) by expanding IFN-γ+CD8+ tumor-infiltrating lymphocytes (7-fold) and enhancing splenic IFN-γ production (3-fold). This work validates 2-aminoquinazolines as a novel HPK1 chemotype addressing metabolic instability─a key hurdle in kinase drug discovery.